Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.70 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.53 |
| ▸ | HTR6 | P50406 | 8/20 | 0.49 |
| ▸ | HTR7 | P34969 | 3/20 | 0.49 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 2/20 | 0.49 |
| ▸ | HTR5A | P47898 | 2/20 | 0.49 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.49 |
| ▸ | HTR3B | O95264 | 2/20 | 0.49 |
| ▸ | HTR3A | P46098 | 2/20 | 0.49 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.49 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | NCF1 | P14598 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.49 |
| ▸ | HTR1D | P28221 | 1/20 | 0.49 |
| ▸ | HTR1B | P28222 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27658727 | 0.98 | NPC1 (0.68) | NPC1ADRB1HTR6HTR7HTR1A | |
| SCHEMBL5707829 | 0.86 | ADRB1 (0.56) | NPC1ADRB1HTR6HTR7HTR1A | |
| SCHEMBL28713189 | 0.85 | NPC1 (0.51) | NPC1ADRB1HTR6HTR7HTR1A | |
| SCHEMBL109882 | 0.84 | ADRB1 (0.55) | NPC1ADRB1HTR6HTR7HTR1A | |
| SCHEMBL28715613 | 0.84 | NPC1 (0.50) | NPC1ADRB1HTR6HTR7HTR1A | |
| SCHEMBL1742844 | 0.84 | ADRB1 (0.59) | NPC1ADRB1HTR6HTR7HTR1A | |
| SCHEMBL21122344 | 0.84 | ADRB1 (0.59) | NPC1ADRB1HTR6HTR7HTR1A | |
| SCHEMBL31565663 | 0.84 | NPC1 (0.96) | NPC1TSHRHSD17B10KDM4EALDH1A1 | |
| SCHEMBL3654065 | 0.84 | NPC1 (0.96) | NPC1TSHRHSD17B10KDM4EALDH1A1 | |
| SCHEMBL17009548 | 0.84 | NPC1 (0.89) | NPC1TSHRHSD17B10KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | FUTURE MEDICINE CO., LTD. (KR) | 2024-06-20 | — | — | US | claimed |
| EP-4296273-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | Future Medicine Co., Ltd. (KR) | 2023-12-27 | — | — | EP | claimed |
| CN-117083286-A | Pair A 2A A is a 3 Adenosine derivatives having antagonism to adenosine receptor and process for preparing same | 未来制药有限公司 | 2023-11-17 | — | — | CN | claimed |
| WO-2022203427-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | 퓨쳐메디신 주식회사 | 2022-09-29 | — | — | WO | claimed |
| CN-108863949-B | Capsaicin receptor antagonist for treating chronic inflammatory pain and synthetic method | 湖南博隽生物医药有限公司 | 2021-01-15 | — | — | CN | claimed |
| CN-111393380-A | Capsaicin receptor antagonist for treating chronic inflammatory pain | 湖南博隽生物医药有限公司 | 2020-07-10 | — | — | CN | claimed |
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | claimed |
| CN-103655569-B | N-(pyridin-4-yl) purposes of piperazine-1-Methanamide | TIANJIN HONGRI PHARMACEUTICAL INDUSTRY CO., LTD. (CN) | 2016-02-10 | — | — | CN | claimed |
| WO-2015154064-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2015-10-08 | — | — | WO | claimed |
| US-7964605-B2 | Phenyl piperazine compounds, pharmaceutical composition comprising the same, and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-06-21 | — | — | US | claimed |
| US-20090298851-A1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND USE THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-12-03 | — | — | US | claimed |
| WO-2009145590-A2 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2009-12-03 | — | — | WO | claimed |
| US-20250236608-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-07-24 | — | — | US | disclosed |
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PFIZER INC. (US) | 2024-07-25 | — | — | US | disclosed |
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | FUTURE MEDICINE CO., LTD. (KR) | 2024-06-20 | — | — | US | disclosed |
| WO-2024121779-A1 | PAPAIN-LIKE PROTEASE (PLPRO) INHIBITORS | PFIZER INC. (US) | 2024-06-13 | — | — | WO | disclosed |
| EP-0809642-A1 | IMIDAZO 1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1997042956-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0737189-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 1996-10-16 | — | — | EP | disclosed |
| WO-1996025414-A1 | IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298851-A1 | PHENYL PIPERAZINE COMPOUNDS, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AND USE THEREOF | GRIK5, PLP2, PMP22 | NPC1 236/4885ADRB1 1434/4885HTR6 557/4885 |
| US-20240245673-A1 | Papain-like protease (PLpro) inhibitors | PREP, PEPD, ACE | NPC1 1614/4885ADRB1 3673/4885HTR6 3633/4885 |
| US-20250236608-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | NPC1 1417/4885ADRB1 3808/4885HTR6 3163/4885 |
| US-20240199679-A1 | ADENOSINE DERIVATIVE HAVING ANTAGONISTIC ACTION ON A2A AND A3 ADENOSINE RECEPTORS AND METHOD FOR PREPARING SAME | ADORA2A, ADORA3, ADORA2B | NPC1 2082/4885ADRB1 39/4885HTR6 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.